The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies

SpringerPlus

Volumn 3, Issue 1, 2014, Pages

  Feldman, Gregory J ^a   Bernstein, Jonathan A ^b   Hamilton, Alan ^c   Nivens, Michael C ^d   Korducki, Lawrence ^e   LaForce, Craig ^f  

^a S Carolina Pharmaceutical Research   (United States)

^b Bernstein Clinical Research Center   (United States)

^c BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f North Carolina Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84922361469     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-419     Document Type: Article

References (17)

1. Beier J, Kirsten A-M, Mróz R, Segarra R, Chuecos F, Caracta C, Garcia Gil E: Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study.COPD 2013, 10:511–522. 10.3109/15412555.2013.814626
2. 2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models.J Pharmacol Exp Ther 2010, 334:53–62. 10.1124/jpet.110.167007
3. 2-adrenoceptor agonist with a 24 h bronchodilatory efficacy.Bioorg Med Chem Lett 2010, 20:1410–1414. 10.1016/j.bmcl.2009.12.087
4. European Medicines Agency: Guideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD). 2012.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/08/WC500130880.pdf
5. Ferguson G, Feldman G, Hofbauer P, Hamilton A, Allen L, Korducki L, Sachs P: Lung function efficacy of olodaterol QD delivered via Respimat in COPD patients: Results from two 48-week studies [abstract].Eur Respir J 2013,42(Suppl 57):5s. abstract 187
6. Global Initiative for Chronic Obstructive Lung Disease: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013.http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf
7. 1profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting B2-agonist, in patients with COPD [abstract].Am J Respir Crit Care Med 2012, 185:abstract A2930.
8. Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, Paggiaro P: Lung function efficacy of olodaterol QD delivered via Respimat versus placebo and formoterol BID in patients with COPD: two 48-week studies. Poster P764 presented at the European Respiratory Society Annual Congress, Barcelona, Spain; 2013.
9. 1time profile of olodaterol QD delivered via Respimat® in COPD: Results from two 6-week studies [abstract].Eur Respir J 2013,42(Suppl 57):982s. abstract 4635
10. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: Standardisation of spirometry.Eur Respir J 2005, 26:319–338. 10.1183/09031936.05.00034805
11. 2-agonist, in patients with mild asthma.J Allergy Clin Immunol 2009, 124:1217–1221. 10.1016/j.jaci.2009.08.047
12. O’Byrne PM, D’Urzo T, Gahlemann M, Hart L, Wang F, Beck E: Dose-finding study of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma [abstract].Am J Respir Crit Care Med 2012, 185:abstract A3963.
13. Rodrigo GJ, Neffen H: Comparison of indacaterol with tiotropium or twice-daily long-acting β-agonists for stable COPD: a systematic review.Chest 2012, 142:1104–1110. 10.1378/chest.11-2252
14. Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS: Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs.Respir Med 2011, 105:435–441. 10.1016/j.rmed.2010.09.006
15. US Department of Health and Human Services: Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. 1998.http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078749.pdf
16. van Noord JA, Korducki L, Hamilton A, Koker P: Four weeks once daily treatment with BI 1744 CL, a novel long-acting β2-agonist, is effective in COPD patients [abstract].Am J Respir Crit Care Med 2009, 179:abstract A6183.
17. 2-agonist olodaterol in COPD.Pulm Pharmacol Ther 2011, 24:666–672. 10.1016/j.pupt.2011.07.006